Female libido-enhancing pill Addyi has hit store shelves. The drug can't be taken with alcohol or certain other drugs, which likely will limit its use. Experts, however, maintain that the restrictions could lead to development of better treatments for sexual problems of the women.

Kim Wallen, a psychology professor at Emory University, said Addyi has the potential to pave the way for the manufacturing of more drugs targeting desire in men and women. Where Viagra and other drugs for men's erectile dysfunction work by increasing blood flow to the genitals, Addyi works by acting acts on brain chemicals associated with desire.

"This is the first time that a drug, for either men or women, has been approved strictly to increase sexual desire," Wallen said. "That legitimizes many other drugs that are in development."

Treatments for libido issues of women are still a huge untapped market for drugmakers. Analysts estimate the market could be worth over $2 billion, based on estimates that around 9 million women in the US may suffer from desire disorders. But no major drugmaker has made this a research priority so far. In the 1990s, Pfizer, Bayer and Procter & Gamble all studied this but then discarded the idea.

Addyi was developed by the German conglomerate, Boehringer Ingelheim and was later sold to Sprout Pharmaceuticals after the medication was rejected by Food and Drug Administration due to lackluster effectiveness and issues like nausea, fatigue and dizziness.

Sprout finally managed to win FDA approval for Addyi after four years. The drug will come with a bold warning label about the risks of fainting if taken together with alcohol or certain medications.